A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD

A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD

Autor Abdallah, Chadi G. Google Scholar
Coplan, Jeremy D. Google Scholar
Jackowski, Andrea Autor UNIFESP Google Scholar
Sato, Joao R. Autor UNIFESP Google Scholar
Mao, Xiangling Google Scholar
Shungu, Dikoma C. Google Scholar
Mathew, Sanjay J. Google Scholar
Instituição Suny Downstate Med Ctr
Yale Univ
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do ABC (UFABC)
Cornell Univ
Baylor Coll Med
Resumo Anxiolytic benefit following chronic treatment with the glutamate modulating agent riluzole in patients with generalized anxiety disorder (GAD) was previously associated with differential changes in hippocampal NAA concentrations. Here, we investigated the association between hippocampal volume and hippocampal NAA in the context of riluzole response in GAD. Eighteen medication-free adult patients with GAD received 8-week of open-label riluzole. Ten healthy subjects served as a comparison group. Participants underwent magnetic resonance imaging and spectroscopy at baseline and at the end of Week 8. GAD patients who completed all interventions were classified as remitters (n=7) or non-remitters (n=6), based on final Hamilton Anxiety Rating Scale (HAM-A) scores <= 7. At baseline, GAD patients had a significant reduction in total hippocampal volume compared to healthy subjects (F-(1,F-21)=6.55, p=0.02). This reduction was most pronounced in the remitters, compared to non-remitters and healthy subjects. Delta (final-baseline) hippocampal volume was positively correlated with delta NAA in GAD. This positive association was highly significant in the right hippocampus in GAD [r=0.81, p=0.002], with no significant association in healthy subjects [Fisher r-to-z p=0.017]. Across all GAD patients, delta hippocampal volume was positively associated with improvement in HAM-A (r(spearman) =0.62, p=0.03). These preliminary findings support hippocampal NAA and volume as neural biomarkers substantially associated with therapeutic response to a glutamatergic drug. (c) 2012 Elsevier B.V. and ECNP. All rights reserved.
Palavra-chave Riluzole
Generalized anxiety disorder
Hippocampal volume
Magnetic resonance spectroscopy
Idioma Inglês
Financiador Brain and Behavior Research Foundation
Sackler Institute of Columbia University
National Institute of Mental Health
National Institute on Drug Abuse
Alexza Pharmaceuticals
Department of Veterans Affairs
Número do financiamento National Institute of Mental Health: K23-MH-069656
National Institute on Drug Abuse: T32-DA-022975
Data de publicação 2013-04-01
Publicado em European Neuropsychopharmacology. Amsterdam: Elsevier B.V., v. 23, n. 4, p. 276-284, 2013.
ISSN 0924-977X (Sherpa/Romeo, fator de impacto)
Publicador Elsevier B.V.
Extensão 276-284
Fonte http://dx.doi.org/10.1016/j.euroneuro.2012.05.009
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000318057500002
Endereço permanente http://repositorio.unifesp.br/handle/11600/36159

Exibir registro completo


Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções



Minha conta